Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts
Pagina: «« 1 ... 69 70 71 72 73 74 »» | Laatste | Omlaag ↓
  9. [verwijderd] 5 november 2010 18:58

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zo zijn er meer vlielander, triest maar waar, ik heb deze ook nog gehad, wel mooi dat je precies een jaar later eraan denkt hier te posten.
  10. [verwijderd] 8 november 2010 21:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Hee Nieuws!!!!!!!!!

    Calypte Biomedical Awarded Therapeutic Discovery Project Grant
    Calypte Biomedical Awarded Therapeutic Discovery Project Grant
    Nov. 8, 2010 (GlobeNewswire) --

    PORTLAND, Ore., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (Pink Sheets:CBMC), the developer, manufacturer and marketer of the Aware™ HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

    The QTDP tax credit is provided under the new section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. The credit is targeted to therapeutic discovery projects that show a reasonable potential to prevent, diagnose, and treat acute and chronic diseases. Allocation of the credit also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life sciences.

    "I am pleased that Calypte has been recognized by this program for having the potential to significantly improve HIV testing and early diagnosis," said Adel Karas, Chairman and CEO of Calypte.

    A leader in HIV diagnostics, Calypte intends to bring to the US market a rapid test for HIV-1/2 using oral fluid instead of blood. Rapid testing results in higher rates of linkage to care than laboratory testing and is widely preferred by patients, while oral fluid testing is less invasive, cheaper and safer than blood tests. Although all reactive rapid test results must be confirmed by laboratory testing, algorithms based on multiple rapid tests have been successfully used in other countries to provide a diagnosis which allows immediate initiation of treatment. Up to half of all clients do not receive their laboratory results, and infected persons who are unaware of their status are not only at increased personal risk through lack of treatment, but are also 3-4 times more likely to transmit HIV than individuals who are aware that they are HIV-positive. Calypte therefore believes that rapid oral fluid testing offers dramatic potential for improvement in HIV medicine. Field trials of Calypte's second generation oral fluid rapid test are underway, in preparation for a US FDA clinical trial in 2011.

    "Calypte exemplifies the cutting-edge, efficient use of resources that is possible in Oregon," said Congressman David Wu, who represents the Portland area in the U.S. House of Representatives. "By funding research projects that can change the course of infectious diseases like HIV, the federal government is helping create jobs and drive economic growth through innovation."

    About Calypte Biomedical Corporation:

    Calypte Biomedical Corporation develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection and other sexually transmitted and chronic diseases. Calypte's product line includes both point-of-care rapid tests and an EIA based incidence test.

    Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. Calypte is the only company to have earned FDA approval for a urine-based HIV-1 antibody-screening test and supplemental Western blot. Today, Calypte's Aware™ family of rapid oral fluid and blood based HIV tests offers flexible testing of HIV 1 and HIV 2 in a non-laboratory setting.

    The Calypte Biomedical Corporation logo is available at www.globenewswire.com/newsroom/prs/?p...

    vr gr willem.
  14. gustaaf1e 16 maart 2011 21:25

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Vlielander,
    Ik had 't gezien.
    Er is sindsdien i.i.g beweging.
    Na zo'n lange stilte blijkt het bedrijf nog steeds springlevend.
    G
  18. gustaaf1e 19 maart 2011 10:54

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Gezien de zgn "tax credit" gelooft men ook op goevernementeel niveau in het bedrijf. Daarnaast nog het pb met de aankondiging van de clinical trial voor FDA goedkeuring en de 100% accurancy resultaten.
    Dat verklaart de opbloeiende handel in het aandeel.
    G
  19. [verwijderd] 21 maart 2011 13:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    van Yahoo geplukt,

    Some of you do not know aht you are talking about when you say 667 M market cap at 667 M share impossible. Look at HTWR at 42B market cap for LVAD at only 200 M market for LVAD. Thw market on HIV diagnostic is 3.5 B and growing. Speculatin that CBMC can take 5-10% of that in the future (or a company that buys CBMC) is certainly within possibility. In fact a 1$ per share CBMC per speculation is more reasobale thant an $84 per share HTWR at a 42 B market cap in a 200 M doallar market potential. HTRW went from .25 to $27 in one day a few years ago, so CBMC can fo .01-.03 up to a dollar w/in a year if not much much sooner. Roth and Stark recently purchased 47M shares of CBMc this past Dec at .03. I dont see a venture group spending $150K on a .006 stock (pps in Dec) unless they know nsomething and see a huge return on the risk. Rating :
    (No ratings)Rate it:
  21. [verwijderd] 16 oktober 2011 14:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    misschien dat dit nieuws wat beweging zet in de koers,

    PORTLAND, Ore., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (OTCBB:CBMC.PK - News), a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has entered into a memorandum of understanding (MoU) with a private investor to secure funding needed to complete the FDA approval procedures for the new product AWARE(TM) 2. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors.

    As announced on March 2, 2011, Calypte successfully completed internal trials on its new AWARE(TM) 2 HIV-1/2 oral fluid rapid test, which showed an accuracy of 100%. Based on these promising results, Calypte has contacted the FDA and started the process to conduct clinical trials.

    "We are extremely pleased that we were able to secure this investment," stated Adel Karas, CEO of Calypte. "It shows continued support and belief in Calypte Biomedical, and was a critical milestone allowing us to move forward with the FDA clinical trials of our AWARE(TM) 2 product that has the potential to significantly improve HIV testing and early diagnosis."
1.470 Posts
Pagina: «« 1 ... 69 70 71 72 73 74 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.192
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.501
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.035
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.042
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.900
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.549
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.976
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390